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Africa is a vast and diverse continent, and this is reflected in multiple facets of healthcare prevention and 
delivery. Africa also shares with many other lower- and middle-income countries (LMIC) the spectre of a 
global epidemic of cardiovascular disease in juxtaposition with a considerable burden of communicable 
diseases.(1) This supplement of the South African Heart Association Journal is centred around the Southern 
African region, but it addresses a wide range of timely issues of relevance not only to other regions of the 
continent but in the context of LMIC and newly industrialised nations around the world. The concept of 
the “epidemiologic transition” provides a very useful framework for understanding epidemiological trends 
in cardiovascular disease against a backdrop of profound changes in many societies evolving from a rural to 
an urban environment and in the face of challenges posed by the newly industrialised societies.(2,3) (Table 1)
Stage 1 (the age of pestilence and famine) still exists in parts of sub-Saharan Africa, Southeast Asia, and parts 
of Latin America. Stage 2 (the phase of “receding pandemics”) was present in the United States around 
the first twenty years of the 20th century. During this phase the predominance of cardiovascular deaths 
are secondary to rheumatic heart disease and haemorrhagic strokes. Stage 3 (the phase of degenerative 
and man-made diseases) was characterised by the rapidly expanding epidemic of cardiovascular disease in 
the United States from the 1920s to the 1960s, and in Western Europe this occurred approximately ten 
years later. In this phase of the epidemic, coronary heart disease is initially seen in patients of higher socio-
economic status. Stage 4 (which is the phase of delayed degenerative diseases) is the situation in most of 
the United States, Western Europe, and Australia, and is characterised by a reduction in age-adjusted 
cardiovascular deaths, but an overall increase in cardiovascular death is the longevity as the population 
increases. During stage 4 of the epidemic, premature cardiovascular death manifests primarily in patients of 
lower socio-economic status. 
A pivotal question facing these countries such as the United States and Western Europe, which have 
experienced a consistent reduction in cardiovascular mortality over four decades, is whether the epidemic 
of obesity, diabetes, and hypertension will reverse the hard won gains. The decline in age-adjusted coronary 
heart disease mortality over the last 40 to 50 years has been primarily attributable to control of risk factors 
and, to a lesser extent, upon new therapeutic advances.(4) Signals from a number of different sources 
including epidemiologic studies and autopsy data, suggests that the decline in mortality is levelling off or 
indeed trending upward.(5)
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In a different context, the recent experience in Russia is also of great concern in that it emphasises the 
detrimental effects of social upheaval and economic instability upon the longevity of a population, and in 
particular the impact upon death due to cardiovascular disease, violence, and accidents.(6)
Distribution of the Epidemiologic Transition in Low- and Middle-Income Countries
Although it is generally accepted that an epidemic of premature death due to cardiovascular disease is 
occurring on a global scale, it appears likely that the brunt will be born by low- and middle-income countries, 
which are perhaps at the greatest potential disadvantage of combating this threat. Nonetheless, it is a 
mistake to consider the developing world as a homogonous entity from a health perspective, and each 
region has to deal with its own challenges from an epidemiologic, resource, and infrastructural standpoint. 
A recent analysis by Gaziano, et al. highlights the different stages of the epidemiologic transition present 
within regions falling under the umbrella of the LMIC.(1,2) Cardiovascular and other non-communicable 
diseases are the leading cause of death in Eastern Europe and Central Asia, the Middle East, North Africa, 
East Asia and the Pacific, Latin America, Caribbean, and South Asia, but non-communicable diseases still 
predominate in sub-Saharan Africa. Although phase III of the epidemiologic transition predominates in 
Eastern Europe, the Middle East, and other regions of the world, phases I, II, and III coexist within the same 
region, e.g., South Asia, East Asia, and the Pacific, parts of Latin America and the Caribbean, and in sub-
Saharan countries such as South Africa. A country like India has to deal with a significant proportion of the 
population who are malnourished and ravaged by communicable diseases, and yet living alongside another 
segment of a young population with an extraordinary high incidence of risk factors for cardio-vascular 
disease. Similarly, South Africa has to deal with the burdens of HIV/Aids, infant and maternal mortality, 
violence, and growing burden of non-communicable diseases and cardiovascular risk factors in addition to 
a high prevalence of rheumatic and congenital heart disease and dilated cardiomyopathy (perhaps nutritional 
from an etiological standpoint).(7)
These data provide a framework for the articles in this supplement which highlight the challenges and 
opportunities provided by a high prevalence of structural heart disease and the looming presence of an 
epidemic of coronary heart disease, hypertension, and diabetes. The challenges are many, but there are 
opportunities too, particularly with regard to developing prevention strategies, since the specific cardio-
vascular risk factors are well documented and constitute important targets for therapy. What a wonderful 
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opportunity to telescope the epidemiologic transition and for primary prevention.(8) The lessons learned 
would benefit the global community and not just South Africans. 
The two cardiac surgical papers by Turina and Kinsley, et al. illustrate quite strikingly the contrast between 
the challenges and the opportunities. Moreover, the two publications emphasise the burden of established 
valvular and congenital heart disease in the developing world in addition to the growing numbers of patients 
with coronary heart disease.
Marko Turina discusses the many challenges involved in transferring knowledge to LMIC, in a discipline as 
complex, labour intensive, and resource hungry such as cardiac surgery. This is an area that has been 
addressed from a number of different perspectives by other European Association for Cardiovascular 
Surgery and other organisations. 
The role of international assistance and development in building and equipping suitable hospitals is an 
obvious solution but one that is not always successful since it requires local expertise to fully utilise the 
facilities. Moreover, this requires “knowledge transfer” and not just bricks and mortar. The other approach 
favoured by non-governmental organisations (NGOs) requires the travel of teams who perform pro-
cedures in specialised hospitals within the developing world. This has the attraction that patients, especially 
children, receive the treatment, but the training of individuals locally is not a priority. As such, this approach 
can only offer an interim solution. Transporting patients to surgical centres in specialised institutions in 
the developed world is a worthy cause from a humanitarian standpoint, but this is an extremely expensive 
approach which can only touch the tip of the iceberg. 
Given these caveats, it is encouraging to note that the focus of the EACTS is on the transfer of knowledge 
via assistance of teaching courses with a comprehensive didactic and practical curriculum with access aided 
by a system of scholarships enabling young surgeons from LMIC to visit advanced centres including the 
EACTS School established in Bergamo, Italy. The essence of this approach is on training with a view to the 
acquired skills being practiced in their native countries. Concern relates to the “brain drain” and the 
need to retain these highly trained professionals in areas in which their skills are direly needed. 
Rob Kinsley’s description of the experience of the Walter Sisulu Paediatric Cardiac Centre for African 
(WSPCCA) highlights the challenges and the magnitude of the need, but also illustrates what can be 
achieved by dedicated individuals in the fields of service, training, and research in the space of only eight 
years. Africa is the most underserved continent in the field of paediatric cardiac surgery; a discipline which 
has progressed to the point where 70 to 80% of children born with cardiac disease can now survive into 
adulthood providing they have access to optimum treatment. Despite the formidable hurdles, the 
WSPCCA has performed 2 023 operations in 1 738 patients of which 53% are neonates and infants under 
one year of age. This includes surgery performed at two centres in Cape Town, in addition to Sunninghill 
Hospital in Gauteng. The results are excellent and provide a service to South Africa and the rest of the 
continent – not only from a clinical standpoint but as an African led centre for training and relevant research. 
15% of patients are funded by the Foundation, and 85% of patients are self-funded. This model of public/























from abroad. The figure of 15% is extremely low considering the quality of the work and the immediate 
benefit. Nonetheless, Kinsley has pointed out that long-term solutions lie in participation by African 
governments and the economies of their own countries and in collaborative efforts like the WSPCCA 
across regional and national boundaries. Until this happens, regrettably “it appears that the African child 
with congenital heart disease will continue to depend upon the benevolence of others for cardiac care”. 
Hopefully, the seeds planted and nurtured by Kinsley and his colleagues will continue to grow and receive 
the support they deserve.
Sandra Pretorius, Simon Stewart and Karin Sliwa review the lessons learnt from the heart of Soweto 
Study. The Heart of Soweto Study provides an example of what can be achieved under difficult eco- 
nomic, infrastructural, and socio-political circumstances.(8) Karen Sliwa and her team have been extremely 
successful in providing South African medicine with a major epidemiologic resource, which could play a 
crucial role in monitoring the potential epidemic of cardiovascular disease and by providing a profile of 
the current distribution of heart disease in a largely black urban African population. This demonstrates an 
extremely low rate of ischaemic heart disease but high rates of hypertensive and valvular heart disease and 
heart failure due to a multiplicity of conditions including hypertension, idiopathic dilated cardiomyopathy, 
isolated right heart failure, and peripartum cardiomyopathy. Tuberculosis pericarditis unfortunately continues 
to be extremely common. Other important observations from the Soweto Heart Study have demonstrated 
the growing prevalence of all the cardiovascular risk factors with the exception of hyperlipidemia and raise 
the issue of whether these are harbingers of an epidemic to come. It appears that the Soweto population 
is standing at the crossroads of new and historically prevalent heart disease and provides an epidemiological 
laboratory for the study of the impact of migration and a changing socio-economic environment upon the 
cardiovascular health of a community in transition. 
Another innovative component of this study is to develop an African cardiovascular risk score. The 
Framingham study has been an unqualified success by identifying the common risk factors underlying the 
development of coronary heart disease and stroke and the benefits have been worldwide. Nonetheless, 
traditional risk scores which are developed in populations such as Framingham may not be directly appli-
cable to other environments from a quantitative standpoint, although the INTERHEART study has taught 
us that the traditional risk factors are certainly the predominant cause of premature cardiovascular disease 
globally. Nonetheless, developing countries face additional challenges from novel risk factors and their 
interaction with the established risk factors may be critically important.(1)
Simon Stewart, who is part of the Heart of Soweto international collaboration, discusses the barriers and 
challenges of the primary and secondary prevention of disease in sub-Saharan Africa. Here again lessons 
learned may be applicable to other parts of the developing world. Although the challenges are enormous 
there is also great potential since the epidemic of coronary heart disease, although projected, has not 
arrived. Risk factors can be modified and there is the possibility that an apparently exorable trend can be 
halted. In many other parts of the world the epidemic of cardiovascular disease is already rampant and the 
time for modifying the epidemiologic transition has already passed. Nonetheless, and in regard to southern 
Africa although the barriers are not insurmountable, current trends in cardiovascular risk factors are not 
encouraging.(9)
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Prevention in sub-Saharan Africa will take many forms including population-based as opposed to individual 
interventions in high-risk populations. In this respect the “polypill” is intriguing and one suspects that if 
the polypill turns out to be successful in a South Asian population, this approach may be translated into 
other parts of the world. A key to this is an understanding that the contribution of risk factors may vary 
among regions and perhaps developing a polypill specific to a particular region.(10) Developing solutions to 
the global epidemic of cardiovascular disease will require research into many other aspects including 
agricultural and food policies, smoking cessation programmes, urban design, air pollution, social and cultural 
values, and economic changes. The Heart of Soweto Study can play an invaluable role in identifying and 
monitoring trends in risk factors for cardiovascular disease and in developing preventive strategies in a 
complex and changing socio-economic milieu. 
The paper by Terblanche and Burgess on cardiovascular clinical trials and clinical research in general in 
Africa focuses upon a critically important area – namely, clinical trials in African patients with both African 
diseases and the emergence of cardiovascular risk factors in the same population. The need for health 
research including trials in LMIC is indisputable, but the African continent’s research output is small and in 
a state of crisis. South Africa is currently leading the way as it should given its GDP and its current 
scientific infrastructure and traditions in comparison to other African countries but the road ahead is long 
and strewn with obstacles. 
Marli Terblance and Lesley Burgess highlight the difficulties in performing health research in the African and 
South African environment. They emphasise the lack of funding but also stress other issues that are pivotal 
to well carried out and ethical clinical trials, such as the protection of patient rights, informed consent, the 
language barrier, cultural difficulties, and attitudes, and essential impact of clinical trials on a global scale is 
that the trials in developing countries must fall under the ethical guidelines existing in developed countries. 
A landmark paper by Glickman, et al. addresses social issues raised by clinical trials in vulnerable patient 
populations in the LMIC.(11)
Nonetheless, clinical trials need to be performed to answer research problems of importance in the 
African context, but it is undeniable that they are difficult to accomplish. This is another area, however, 
which is ripe for international collaboration with clinical trial groups that have the respect of the requisite 
experience and infrastructure and, hopefully the interest in making a contribution to research in Africa and 
other parts of the developing world. 
In summary, from the perspective of cardiovascular medicine and other diseases, Southern Africa can be 
viewed as a fascinating epidemiological research laboratory given the mesh of races, changing environments, 
and socio-economic status. There is no shortage of topics to study but developing the research infra-
structure and collaborative networks is a huge challenge. The other side of the coin is characterised by the 
burden of care that needs to be delivered under difficult circumstances and the equally complex challenges 
of primary and secondary prevention. This issue of the South African Heart Association Journal does not 
shy away from pointing out the obstacles, but a sense of optimism can also be gleaned from all the authors. 
Lessons learned in South Africa will be important from a global perspective as the world begins to focus 
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TABLE 1:  Four stages of the epidemiologic transition (reprinted from reference number 1 with permissions).
* Greater in high socioeconomic groups.  ** Younger pt - lower socio-economic status. Elderly - higher socio-economic status
Description Life expectancy Proportion of death Dominant form of 
  due to CVD (%) CVD death
Stage 1: Pestilence and famine   
Malnutrition 35 yr <10 Infectious (RHD)
Infectious diseases     Nutritional
Stage 2: Receding pandemics   
Improved nutrition and 50 yr 10 - 35 Infectious (RHD) 
public health   
Chronic disease   Stroke - Haemorrhagic
Hypertension 
Stage 3: Degenerative and man-made diseases  
Increased fat and >60 yr 35 - 65 IHD*
caloric intake
Tobacco use
Chronic disease deaths   Stroke - Haemorrhagic 
>Infections, malnutrition        - Ischaemic
Stage 4: Delayed degenerative diseases  
Leading causes of mortality >70 yr 40 - 50 IHD**
CV and cancer deaths
Prevention and Tx delays onset   Stroke - Ischaemic
Age-adjusted CV death reduced   CHF
